Autosomal recessive primary microcephaly (MCPH) is a neurodevelopmental disorder. Mutations in genes that are involved in brain growth and development like proliferation or differentiation of progenitor cells, or cell apoptosis can lead to MCPH.[@b1-asm-6-391] MCPH is marked by a decreased brain size associated with a significantly decreased occipito-frontal circumference (OFC), which is greater than two standard deviations (SD) below the mean values for age, sex and origin.[@b2-asm-6-391] A head circumference less than 3 SD below the age and sex is generally taken as the clinical demarcation of MCPH.[@b3-asm-6-391] The prevalence of MCPH varies worldwide ranging between 1.3 to 150 per 100 000 births depending on level of consanguinity and population type.[@b4-asm-6-391] In MCPH, the brain size is reduced substantially though the overall brain architecture is not much affected.[@b5-asm-6-391]

To date, 17 genes (MCPH1-MCPH17) have been discovered; mutations lead to MCPH.[@b6-asm-6-391] Most of the mutations that are reported in these genes are nonsense mutations or frameshift mutations that produce non-functional truncated proteins.[@b7-asm-6-391] Mutations in the abnormal spindle-like microcephaly-associated (*ASPM*) gene cause the most prevalent form of microcephaly (25--50%) known as MCPH5.[@b2-asm-6-391],[@b8-asm-6-391]--[@b23-asm-6-391] The genetic basis of brain evolution in primates including humans, involves the ASPM gene.[@b24-asm-6-391]--[@b27-asm-6-391] The ASPM protein is mostly found in the nucleus, but moves to the spindle poles during mitosis, indicating its possible role in keeping the integrity of spindle/centrosome.[@b28-asm-6-391]

The advent of state of the art techniques like next generation sequencing made it possible to discover the underlying genetic causes of inherited disorders with greater precision and so broaden the existing spectrum of genetic mutations. There are quite a few reports on the syndromic form of genetic microcephaly in Saudi families.[@b29-asm-6-391],[@b30-asm-6-391] Recently, a splice donor site mutation in a *CIT* gene was identified in a Saudi family with a nonsyndromic genetic form of microcephaly.[@b31-asm-6-391] To the best of our knowledge, this is the only gene known for nonsyndromic form of microcephaly in a Saudi family.

In this study, we report a novel, homozygous, splicesite acceptor mutation affecting exon 16 of the *ASPM* gene, causing nonsyndromic form of microcephaly in a Saudi family. The mutation has been identified using the approach of whole exome sequencing of the index patient.

PATIENTS AND METHODS
====================

Permission to undertake this study was granted by Ethical Review Committee of Taibah University Almadinah Almunawwarah, Saudi Arabia. Before commencing the study, informed written consent for genetic analysis was obtained from parents. Parents denied consent for publishing clinical photographs. Genetic analysis including DNA extraction, whole exome sequencing and Sanger sequencing was performed in the Centre for Genetics and Inherited Diseases, Taibah University.

A Saudi family with two affected individuals having primary microcephaly was recruited for this study. The affected individual was examined clinically as well as radiologically by a paediatric neurologist at Madinah Maternity and Children Hospital, Almadinah. The family pedigree consisting of four generations was drawn after querying the concerned family.

DNA extraction
--------------

Blood samples from 10 individuals (III-2, III-3, III-4, III-5, III-6, III-7, IV-1, IV-2, IV-3, IV-5) including two affected individuals (IV-1, IV-2) were collected in EDTA containing vacutainers. Genomic DNA extraction was done using the QIAquick DNA extraction kit. DNA quantification and concentration was determined by Nanodrop spectrophotometer (Green BioResearch Baton Rouge, LA, USA) and Qubit fluorometer (ThermoFisher Scientific Inc, Massachusetts, USA). The DNA integrity was resolved through 1% agarose gel electrophoresis.

Laboratory investigations
-------------------------

Laboratory investigations including measurement of amino acid levels, creatine and creatinine level as well as blood and urine proﬁle were performed to exclude metabolic disorders like phenylketonuria, phosphoglycerate dehydrogenase deficiency and 2-ketoglutaric aciduria. Thyroid function tests were performed to measure TSH, T4, T3 and free T4. Ophthalmic examination was performed to exclude issues related to eye including bilateral macular and perimacular lesions as well as optic nerve abnormalities. Diagnostic measurements of head circumference (HC) of the affected members and magnetic resonance imaging (MRI) of the brain was done at Madinah Maternity and Children Hospital.

Whole exome sequencing
----------------------

DNA from the affected members (IV-1, IV-2) of the family was subjected to whole exome sequencing. Library preparation and exome enrichment was done by using Nextra Rapid capture Exome Kit that captures 214 405 exons and splice-site with 98.3% RefSeq coverage. DNA sequencing and cluster generation was carried out on NextSeq500 machine (Illumina, San Diego, California, USA).

In brief, 50 ng of genomic DNA was fragmented enzymatically to generate 150--200 bp fragments, followed by tagging with paired end adaptor sequences (tagmentation). The tagmented DNA was then purified and amplified. Resultant library was purified using magnetic beads. The targeted regions were captured using whole exome oligos followed by amplification of the enriched library through polymerase chain reaction. A Qubit fluorometer was used to quantify the enriched library while average library size distribution was calculated through Agilent Bioanalyzer. For cluster generation and sequencing, the quantified DNA library was loaded on the flow cell of the Illumina NextSeq500 instrument. NextSeq500 instrument generates bcl files which were subsequently converted to fastq files using the BCL2FASTQ tool. We used BaseSpace incorporated BWA aligner to align fastq files to the reference genome using BWA-MEM algorithm. Variants calling was done by using genome analysis tool kit (GATK). Genomic variants were filtered and annotated by VariantStudio (Illumina, San Diego, California, USA).

Sanger sequencing
-----------------

The confirmation of the variants discovered by WES was done by Sanger sequencing. Ensembl genome browser (*<http://asia.ensembl.org/index.html>*) was used to download the 10877 base pairs genomic sequence of the *ASPM* gene (ENST00000367409.8). Primers were designed using primer3 software (*<http://frodo.wi.mit.edu/primer3/>*) to amplify the variants along with their flanking sites. Resultant sequence variants were identified using BIOEDIT sequence alignment editor version 6.0.7 (Ibis Biosciences Inc., Carlsbad, CA, USA).

RESULTS
=======

A consanguineous Saudi family, inheriting autosomal recessive primary microcephaly with two living affected members born to phenotypically normal parents, was recruited for this study ([Figure 1](#f1-asm-6-391){ref-type="fig"}). The age of the affected individuals IV-1 and IV-2 were 18 and 15 years, respectively. Affected individual IV-4 exhibited similar clinical features to individuals IV-1 and IV-2. She died at the age of 9 after developing high grade fever. Laboratory investigations including measurement of amino acid levels, creatine and creatinine level as well as blood and urine proﬁle excluded any metabolic disorder. Thyroid function tests revealed a normal functioning thyroid. Ophthalmic examination excluded issues related to eye/vision. Clinical examination showed a small head with bi-temporal narrowing. Occipitofrontal circumference (OFC) for affected individuals IV-1 and IV-2 were 41cM and 45 cM, respectively. Both parents showed normal intelligence scores and normal HC. Sloping forehead in both cases was evident. Both affected children showed intellectual disability and speech delay, although no hearing impairment was observed. Patient IV-2 developed epilepsy at the age of 6 years and is currently taking carbamazepine and valproic acid. Magnetic resonance imaging (MRI) of the brain revealed a parieto-occipital and left temporo-occipital gyration defects in patient IV-2. Both patients showed short stature (height is less than 2.5 SD).

Exome data analysis
-------------------

The resulting VCF (variant call format) file contains approximately 85 000 variants. These variants were filtered based on quality, frequency, genomic position, protein effect, pathogenicity and previous associations with the phenotype. Candidate variants were expected to follow an autosomal recessive inheritance pattern. Rare, potentially harmful variants present in the homozygous state were of primary interest due to the positive consanguinity for this family. Looking for rare homo/hemizygous variants within the protein coding regions of all genes that have previously been associated with MCPH phenotype including *MCPH1, WDR62, CDK5RAP2, CASC5, ASPM, CENPJ, STIL, CEP135, CEP152, ZNF335, PHC1, CDK6 CENPE, SASS6, MFSD2A, ANKLE2* and *CIT* yielded one plausible candidate (c.3742-1G\>C) in the *ASPM* gene. The genomic position of this variant is chr1:197091174 according to the Ensembl transcript number ENST00000294732. Mutations in ASPM are associated with autosomal recessive primary microcephaly, type 5. Thereafter, rare, potentially harmful variants present in those genes in (compound) heterozygous state were further considered. However, this approach did not yield additional plausible candidates. The analysis was then expanded to all genes, whereby we first focused on potentially harmful homozygous variants and then moved on to potential candidates in the (compound) heterozygous state. However, none of these approaches yielded good candidate variants.

Validation through Sanger sequencing and segregation analysis
-------------------------------------------------------------

Intron 15--16 and exon 16 of the ASPM gene was sequenced by the Sanger approach in all 10 available DNA samples of a family members to validate the identified mutation. Sanger sequencing validates the exome discovered splice-site mutation in both affected individuals and confirmed the segregation of same mutation in the whole family. Unaffected parents were found heterozygous for this mutation ([Figure 2](#f2-asm-6-391){ref-type="fig"}).

In silico analysis of splice-site variant
-----------------------------------------

The variant identified in this study in the ASPM gene occurs at a splice acceptor site. In silico analysis with different splice-site effect prediction tools including human splicing finder (*<http://www.umd.be/HSF3/>*), SpliceView *(<http://bioinfo.itb.cnr.it/oriel/splice-view.html>*), Sroogle (*<http://sroogle.tau.ac.il/>,* SplicePort *(<http://spliceport.cbcb.umd.edu/>*), Spliceman,[@b32-asm-6-391] GeneID,[@b33-asm-6-391] MaxEnt,[@b34-asm-6-391] ASSP,[@b35-asm-6-391] and NNSPLICE[@b36-asm-6-391] predicted this variant to abolish the splice acceptor site.

DISCUSSION
==========

A novel homozygous variant altering the splice-site acceptor sequence (c.3742-1G\>C) preceding exon 16 of the *ASPM* gene was detected in two patients with MCPH. The variant perfectly segregates with the disease phenotype in a family. This variant is predicted to cause skipping of exons 16. Skipping of exon 16 is predicted to change the order and number of IQ motifs in the resulting protein leading to typical MCPH phenotype ([Figure 3](#f3-asm-6-391){ref-type="fig"}).

MCPH is a heterogenetic disorder with numerous genes known to cause the MCPH phenotype when mutated. ASPM gene (MCPH5) occupies the most prominent position in disease aetiology of MCPH owing to its mutations rate, which is as high as 40%.[@b19-asm-6-391] Different ethnic populations show different prevalences for the MCPH5 locus. For instance, in Pakistan this toll falls in the range of 43--86%,[@b15-asm-6-391] in Indian populations it is 33.5%,[@b12-asm-6-391] while in Iranian population it is reported to be 13.3%.[@b21-asm-6-391]

The ASPM protein is essential for normal mitotic spindle function in embryonic neuroblasts. By promoting the division of neural progenitor cells during early brain development, ASPM helps determine the total number of neurons and the overall size of the brain.[@b10-asm-6-391] Defects in the ASPM protein are associated with autosomal recessive microcephaly, and mild to severe mental retardation. Delayed motor and speech development are frequent symptoms of this condition.[@b9-asm-6-391],[@b19-asm-6-391] Mutations in *ASPM* are associated with autosomal recessive primary microcephaly, type 5 (MCPH5), which is characterized by decreased occipitofrontal circumference, usually less than 3 SD of the mean, present at birth and associated with mental retardation and speech delay. Other features may include short stature or mild seizures. MCPH5 is associated with a simplification of the cerebral cortical gyral pattern in some cases, which is considered within the phenotypic spectrum of primary microcephaly. [@b5-asm-6-391],[@b9-asm-6-391],[@b20-asm-6-391] Pathogenic *ASPM* mutations are typically truncating (nonsense, frameshift or splice affecting variants). Hence, the probable disease mechanism leading to primary microcephaly was nonsense mediated decay of the ASPM mRNA leading to a pronounced reduction of the protein in neuroepithelial cells.[@b19-asm-6-391]

The detected novel variant is located at a splice-site acceptor of the *ASPM* gene (between exons 15--16). The variant is predicted to have an effect on splicing according to the scores of Jian et al (SC Ada, SC RF).[@b37-asm-6-391] In addition, an alteration of splicing due to this variant is also predicted by the in silico tool Human Splice Finder (see *<http://www.umd.be/HSF3/>*) (the in silico analysis indicates that this variant could lead to a broken WT acceptor site, most probably affecting splicing). Functional experiments are however needed to assess this hypothesis. Interestingly, a few mutations in the close proximity of this variant are described as pathogenic (p.Glu1266Term, rs199422161; splice variant, c.3741+1G\>A, rs199422160; R1271\*; rs140602858), providing further support for this variant as a plausible candidate to explain the patient's phenotype in this family.[@b11-asm-6-391],[@b19-asm-6-391] Nicholas et al[@b19-asm-6-391] have studied cohorts of microcephalic children to extend both the phenotype and the mutation spectrum and identified a Caucasian patient carrying a homozygous splice-site mutation (c.3741+1G\>A) only one residue away from the variant detected here, hence affecting the same splice-site. In conclusion, this variant is likely to contribute to the primary microcephaly reported for this patient.
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